Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Liabilities and Shareholders Equity (2018 - 2025)

Bicycle Therapeutics' Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $717.6 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 25.01% year-over-year to $717.6 million; the TTM value through Dec 2025 reached $3.2 billion, down 10.13%, while the annual FY2025 figure was $717.6 million, 25.01% down from the prior year.
  • Liabilities and Shareholders Equity reached $717.6 million in Q4 2025 per BCYC's latest filing, down from $764.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.1 billion in Q2 2024 to a low of $223.8 million in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $590.8 million, with a median of $513.5 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 197.73% in 2021, then dropped 25.01% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $479.8 million in 2021, then decreased by 14.42% to $410.6 million in 2022, then surged by 44.99% to $595.3 million in 2023, then soared by 60.73% to $956.9 million in 2024, then dropped by 25.01% to $717.6 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Liabilities and Shareholders Equity are $717.6 million (Q4 2025), $764.0 million (Q3 2025), and $832.2 million (Q2 2025).